There are currently 973 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
QTX3046 in Patients with KRAS G12D Mutations
NCT06428500
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: South Texas Accelerated Research Therapeutics, LLC San Antonio, San Antonio, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Texas Oncology-San Antonio Medical Center, San Antonio, Texas
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Methodist San Antonio, San Antonio, Texas
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Register for Updates
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NCT05745285
Recruiting
The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Mays Cancer Center at UT Health San Antonio, San Antonio, Texas
Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Register for Updates
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656
Recruiting
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following: • Pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Methodist Hospital, San Antonio, Texas +1 locations
Conditions: Septic Shock
Register for Updates
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333015
Recruiting
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/04/2025
Locations: Site 112, San Antonio, Texas
Conditions: Cataract
Register for Updates
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
NCT04762641
Recruiting
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progressive locally advanced (unresectable) or metastatic solid tumors who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 3... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Small Nerve Fiber Activity in Patients with Carpal Tunnel Syndrome Assessed Via Quantitative Sensory Testing
NCT06550284
Recruiting
The diagnosis of carpal tunnel syndrome (CTS) is typically based on clinical findings and confirmatory electrodiagnostic testing. However, electrodiagnostic testing can only assess large A-alpha and A-beta nerve fibers. Quantitative sensory testing (QST) is a series of tests used to assess small nerve fiber changes in the A-delta, c-fibers, and A-beta nerve fibers as well. Previous studies have used QST to assess small nerve fiber changes related to carpal tunnel syndrome and found changes compa... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: Brooke Army Medical Center, San Antonio, Texas
Conditions: Carpal Tunnel Syndrome
Register for Updates
AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal
NCT06264232
Recruiting
The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. All patients will undergo surgery in both eyes, and they will receive follow up care for up to 6-months. During this time, all patients will undergo thorough eye exams at every study visit and complete... Read More
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
02/03/2025
Locations: PNV Clinical Research, San Antonio, Texas
Conditions: Cataract Senile
Register for Updates
Study of PYX-201 in Solid Tumors
NCT05720117
Recruiting
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: NEXT San Antonio, San Antonio, Texas
Conditions: Solid Tumor, Advanced Solid Tumor
Register for Updates
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
NCT06108076
Recruiting
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Register for Updates
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
NCT03560323
Recruiting
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class II-III New York Heart Association (NYHA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Heart Failure, Type 2 Diabetes Mellitus
Register for Updates